The Proclaimsm (Proleukin® Observational Study to Evaluate Treatment Patterns and Clinical Response in Malignancy) Study: The Response Rates for High Dose Interleukin-2 (HD IL-2) Therapy

被引：0
|
作者：
Kaufman, Howard [1 ]
McDermott, David [2 ]
Morse, Michael [3 ]
Lowder, James [4 ]
Wong, Michael [5 ]
机构：
[1] Rush Univ, Chicago, IL 60612 USA
[2] Harvard Univ, Boston, MA 02115 USA
[3] Duke Univ, Durham, NC USA
[4] Prometheus Labs Inc, San Diego, CA USA
[5] Univ So Calif, Los Angeles, CA USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2012年 / 35卷 / 09期
关键词：
Interleukin-2; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：749 / 750
页数：2
相关论文
共 29 条
  • [1] The Transient Nature of Significant Toxicities Associated With High Dose Interleukin (HD IL-2): Preliminary Data From The ProclaimSM Study
    Wong, Michael K.
    Kaufman, Howard L.
    Morse, Michael
    McDermott, David F.
    Lowder, James N.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 753 - 754
  • [2] Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
    Fishman, M.
    Dutcher, J. P.
    Clark, J., I
    Alva, A.
    Miletello, G. P.
    Curti, B.
    Agarwal, Neeraj
    Hauke, R.
    Mahoney, K. M.
    Moon, H.
    Treisman, J.
    Tykodi, S. S.
    Daniels, G.
    Morse, M. A.
    Wong, M. K. K.
    Kaufman, H.
    Gregory, N.
    McDermott, D. F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions
    Marabondo, Stephen
    Kaufman, Howard L.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1347 - 1357
  • [4] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
    Buchbinder, Elizabeth I.
    Gunturi, Anasuya
    Perritt, Jessica
    Dutcher, Janice
    Aung, Sandra
    Kaufman, Howard L.
    Ernstoff, Marc S.
    Miletello, Girald P.
    Curti, Brendan D.
    Daniels, Gregory A.
    Patel, Sapna P.
    Kirkwood, John M.
    Hallmeyer, Sigrun
    Clark, Joseph I.
    Gonzalez, Rene
    Richart, John M.
    Lutzky, Joe
    Morse, Michael A.
    Sullivan, Ryan J.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [5] IMMUNOENDOCRINE THERAPY WITH INTERLEUKIN-2 (IL-2) AND MEDROXYPROGESTERONE ACETATE (MPA) - A RANDOMIZED STUDY WITH OR WITHOUT MPA IN METASTATIC RENAL-CANCER PATIENTS DURING IL-2 MAINTENANCE TREATMENT AFTER RESPONSE OR STABLE DISEASE TO IL-2 SUBCUTANEOUS THERAPY
    LISSONI, P
    BARNI, S
    TANCINI, G
    BRIVIO, F
    CARDELLINI, P
    VAGHI, M
    FOSSATI, V
    FRIGERIO, F
    TUMORI, 1993, 79 (04) : 246 - 249
  • [6] Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study
    Lagan, Jakub
    Naish, Josephine H.
    Fortune, Christien
    Campbell, Christopher
    Chow, Shien
    Pillai, Manon
    Bradley, Joshua
    Francis, Lenin
    Clark, David
    Macnab, Anita
    Nucifora, Gaetano
    Dobson, Rebecca
    Schelbert, Erik B.
    Schmitt, Matthias
    Hawkins, Robert
    Miller, Christopher A.
    DIAGNOSTICS, 2022, 12 (06)
  • [7] High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
    Davar, Diwakar
    Ding, Fei
    Saul, Melissa
    Sander, Cindy
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Tawbi, Hussein A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [8] Treatment of Transmissible Venereal Tumors in Dogs with Intratumoral Interleukin-2 (IL-2). A Pilot Study
    Den Otter, Willem
    Hack, Margot
    Jacobs, John J. L.
    Tan, Jurgen F. V.
    Rozendaal, Lawrence
    Van Moorselaar, R. Jeroen A.
    ANTICANCER RESEARCH, 2015, 35 (02) : 713 - 717
  • [9] High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study
    HC Toh
    SL McAfee
    R Sackstein
    P Multani
    BF Cox
    R Garcia-Carbonero
    C Colby
    TR Spitzer
    Bone Marrow Transplantation, 2000, 25 : 19 - 24
  • [10] High-dose cyclophosphamide plus carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study
    Toh, HC
    McAfee, SL
    Sackstein, R
    Multani, P
    Cox, BF
    Garcia-Carbonero, R
    Colby, C
    Spitzer, TR
    BONE MARROW TRANSPLANTATION, 2000, 25 (01) : 19 - 24
123